SHR2554

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Follicular Lymphoma

Conditions

Follicular Lymphoma

Trial Timeline

Apr 1, 2024 → Apr 1, 2027

NCT ID

NCT06368167

About SHR2554

SHR2554 is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Follicular Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06368167. Target conditions include Follicular Lymphoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06368167	Phase 2	Recruiting	Apr 1, 2024	Apr 1, 2027	Follicular Lymphoma
NCT04335266	Phase 1	Completed	Aug 6, 2019	Mar 30, 2020	Healthy Adult Subjects
NCT03603951	Phase 1	Active	Aug 14, 2018	Aug 14, 2026	Relapsed or Refractory Mature Lymphoid Neoplasms

Competing Products

20 competing products in Follicular Lymphoma

See all competitors

Product	Company	Stage	Hype Score
Enzastaurin	Eli Lilly	Phase 2	52
CT-P10 + Rituxan	Celltrion	Phase 3	77
Rituxan + CT-P10 + Cyclophosphamide + Vincristine + Prednisone	Celltrion	Phase 3	77
Tazemetostat	Eisai	Pre-clinical	23
Zandelisib + Rituximab + Bendamustine + CHOP	Kyowa Kirin	Phase 3	77
Pirtobrutinib + Mosunetuzumab	Eli Lilly	Phase 2	52
fludarabine + rituximab + VELCADE	Johnson & Johnson	Phase 2	52
Epcoritamab + Rituximab	AbbVie	Phase 2	52
Epcoritamab + Rituximab + Lenalidomide	AbbVie	Phase 3	77
Ibrutinib + Venetoclax	AbbVie	Phase 1/2	41
Epcoritamab + Prednisone + Rituximab + Lenalidomide + Doxorubicin + Vincristine + Cyclophosphamide + Obinutuzumab + Bendamustine	AbbVie	Phase 3	77
Venetoclax + Bendamustine + Rituximab	AbbVie	Phase 2	52
Acalabrutinib + Obinutuzumab	AstraZeneca	Phase 2	52
Surovatamig + R-CHOP + R-CVP + BR	AstraZeneca	Phase 3	77
Gonal-F (Follitropin alfa)	Merck	Pre-clinical	23
Eltrombopag and Vorinostat	Merck	Phase 2	52
Recombinant-follicle stimulating hormone (r-FSH)	Merck	Pre-clinical	23
Acalabrutinib + Pembrolizumab	Merck	Phase 1/2	41
Rituximab + Autologous dendritic cells + GM-CSF + Pembrolizumab	Merck	Phase 2	52
G100 + Pembrolizumab + Rituximab	Merck	Phase 1/2	41

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved